In colorectal and pancreatic ductal adenocarcinoma (PDAC), the overexpression of PrPC has been shown to confer resistance to anti-cancer drugs, including doxorubicin, etoposide, and vincristine sulfate [64,65,66,67]. This evidence concerns the gene PRNP and pancreatic ductal adenocarcinoma.